Clinical Trial Update: Long-term, Open-label, Safety Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD) [Phase 4]

View source ↗

Summary

This update describes a Phase 4, long-term, open-label safety study of Inebilizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD) that is currently active b…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuromyelitis Optica Spectrum Disorder

Drugs mentioned

• Uplizna (inebilizumab)

Snippet

Sponsor: Amgen | Conditions: Neuromyelitis Optica Spectrum Disorder | Phase 4 | Status: ACTIVE_NOT_RECRUITING